Esperion Therapeutics, Inc..
ESPR.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral, once-daily medicines for the treatment of elevated low-density lipoprotein cholesterol (LDL-C). Their primary focus is on patients with hypercholesterolemia, a condition characterized by high leve...Show More
Better Health for All
-30
Esperion's core products, NEXLETOL and NEXLIZET, are FDA-approved
1
and received Class I, Level A / Level 1a recommendations from major cardiology guidelines for reducing LDL-C and preventing cardiovascular events, indicating exceptional health benefits.
2
The company's entire business is devoted to health improvement, with no revenue from harmful products. However, the products have significant safety concerns, including contraindications for serious hypersensitivity reactions (e.g., angioedema, anaphylaxis),
3
increased risk of gout,
4
and tendon rupture,
5
along with numerous common adverse reactions, but no quantitative rates are provided.
6
For price accessibility, the company offers average copays of $29-$36 for a 30-day supply,
7
and a patient assistance program provides Nexletol for $10 for a three-month supply,
8
with coupons offering up to 80% savings.
9
Despite this, the copay card cannot be combined with government insurance like Medicaid or Medicare, limiting access for vulnerable populations.
10
The company focuses on the statin-intolerant or resistant market,
11
representing approximately 30% of the overall market, but there's no evidence of reaching a broader vulnerable population.
12
Esperion's FY 2025 R&D guidance is $55-$65 million,
13
but the percentage of the budget allocated to health improvement is not specified. The company mentions enhanced patient support programs,
14
but specific funding or impact evaluation details are absent. Esperion has reached settlement agreements with four generic manufacturers,
15
restricting generic entry until April 2040,
16
while some patents expire in March 2036 or June 2040, indicating substantial patent flexibility but not industry-leading.
17
The company's products are indicated to reduce the risk of major adverse cardiovascular events,
18
which are preventative measures. An adverse event reporting line is provided,
19
but no further details on data protection or privacy safeguards are available.
Fair Money & Economic Opportunity
0
No evidence available to assess Esperion Therapeutics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
30
In 2024, the CEO's total compensation was 16 times the median employee compensation.
1
The company experienced a 60% reduction in employees in 2022 due to investor pressure to cut overhead.
2
Employee reviews from 2018-2025 show an overall rating of 2.1 out of 5 stars, with pay and benefits rated 2.9 out of 5 stars, and work-life balance, job security, management, and culture all rated 2.1 out of 5 stars.
3
Fair Trade & Ethical Sourcing
0
No evidence available to assess Esperion Therapeutics, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No evidence available to assess Esperion Therapeutics, Inc. on Honest & Fair Business.
Kind to Animals
0
No evidence available to assess Esperion Therapeutics, Inc. on Kind to Animals.
No War, No Weapons
0
Esperion Therapeutics, Inc. is a pharmaceutical company.
1
Its 2023 Form 10-K annual report explicitly states that the company is not a defense contractor and is not involved in dual-use technologies.
2
The report also indicates that no defense-related assets are mentioned.
3
This confirms that the company's core business does not involve arms or defense activities, nor does it develop or sell dual-use products, and therefore has no defense assets to divest.
Planet-Friendly Business
0
The provided articles do not contain specific, quantifiable data points for any of the Planet-Friendly Business KPIs. While one article mentions the company furnishes proxy materials via the internet to reduce environmental impact, this action is not quantified in a way that aligns with the rubric's specific metrics.
1
Other articles explicitly state a lack of ESG data, carbon emissions, reduction targets, or sustainability initiatives, meaning no evidence is available to score the KPIs.
2
Respect for Cultures & Communities
0
No evidence available to assess Esperion Therapeutics, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
The company states it is compliant with various US privacy laws, including CCPA and CPRA, as well as EU GDPR.
1
Users are granted rights to access, correct, update, and delete their data, and can opt-out of data sales and profiling, with requests processed within 45 days.
2
Data retention practices are based on necessity and legal requirements.
3
Zero Waste & Sustainable Products
-50
Esperion Therapeutics' Third Party Code of Conduct, published in December 2020, expects third parties to appropriately minimize, manage, control, and treat waste, emissions, and discharges.
1
It also requires them to implement controls for the safe handling, movement, storage, recycling, reuse, or management of waste.
2
The company participates in a Product Stewardship Plan for Unwanted Medicine in San Mateo County, CA, which has collected over 178,000 pounds of medicine since 2016, serving as a waste reduction initiative.
3
This program disposes of unwanted medicine at permitted hazardous waste incinerators.
4
While the program's vendors and disposal facilities have incurred fines, such as Clean Harbors Aragonite, LLC with fines totaling over $775,000 and Ross Incineration Services, Inc. with fines totaling over $135,000, there is no evidence of waste disposal violations directly attributed to Esperion Therapeutics in the past three years.
5
The company provides clear disposal information on all products and packaging through the MED-Project Website and educational materials at kiosk drop-off sites, encouraging residents to protect personal information on drug containers.
6